Brief: Hansa Biopharma Q2 Loss Widens To SEK 170.1 Million
19/07/2022 07:16
July 19 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA HALF YEAR REPORT 2022
* Q2 TOTAL REVENUE AMOUNTED TO SEK 26.4M
* Q2 LOSS FOR PERIOD SEK 170.1 MILLION VERSUS LOSS SEK 132.6
MILLION YEAR AGO
Source text for Eikon: ID:nWkr3phCfm
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS